
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
This publication was supported by Janssen Pharmaceuticals, Inc., and is intended for formulary decision makers, population health decision makers, and/or similar entities.
This AJMC® Profiles in Care is an actionable resource for provider organizations seeking to implement a prevention protocol to reduce the incidence of preventable venous thromboembolism in hospitalized medically ill (nonsurgical) patients.






